Cost Sharing for Preferred Branded Drugs in Medicare Part D
JAMA · 01.04.2025 · 333 (13) · 1170
DOI: 10.1001/jama.2024.28092 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA, erschienen am 01.04.2025. Verfasst von Erin Trish und 2 weiteren Autor:innen. Beteiligte Einrichtung: Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
This study uses data from the Centers for Medicare & Medicaid Services Public Use Files to examine the use of co-payments and co-insurance for preferred brand-name drugs among Medicare Part D plans from 2020 to 2024 and characterize beneficiary exposure to these trends.
Autor:innen und Institutionen
- Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.
- Blaylock Health Economics LLC, Reno, Nevada.
Zitieren
APA
Trish, E., Blaylock, B., & Van Nuys, K. (2025). Cost Sharing for Preferred Branded Drugs in Medicare Part D. JAMA, 333(13), 1170. https://doi.org/10.1001/jama.2024.28092
Vancouver
Trish E, Blaylock B, Van Nuys K. Cost Sharing for Preferred Branded Drugs in Medicare Part D. JAMA. 2025;333(13):1170. doi:10.1001/jama.2024.28092
BibTeX
@article{Trish2025,
author = {Trish, Erin and Blaylock, Barbara and Van Nuys, Karen},
title = {Cost Sharing for Preferred Branded Drugs in Medicare Part D},
journal = {JAMA},
year = {2025},
volume = {333},
number = {13},
pages = {1170},
doi = {10.1001/jama.2024.28092}
}
EUVIMED